Skip to main content
    T

    Tela Bio Inc (TELA)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.76
    +0.00 (+0.07%)

    Market Cap: $34.42M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Tela Bio Inc (TELA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Tela Bio (TELA) has a market cap of $34.42M and an enterprise value of $68.05M. Its share count is up 27.01% from a year earlier. It kept -53.57% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 97.73% above the market cap, as debt exceeds cash.

    Market Cap$34.42M
    Enterprise Value$68.05M
    Latest price (Nov 17, 2026)$0.76

    Key Dates

    The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 22, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.48% in the quarter ended Sep 30, 2026 and grew 52.82% a year over 2 years.

    Shares Outstanding57.69M
    Shares Change (YoY)+27.01%
    Shares Change (QoQ)+0.48%
    Share Count Growth (2Y CAGR)+52.82%

    Valuation Ratios

    The price to sales ratio is 0.6x. Its year-end P/S ranged from 0.7x to 10.8x from 2019 to 2025.

    P/S Ratio0.6x
    Forward P/S0.4x

    Price Statistics

    The stock is down 23.74% over 52 weeks and trades 26.21% below its 50-day average.

    Beta (1Y)1.43
    52-Week Change-23.74%
    1-Month Change-21.46%
    3-Month Change+17.79%
    6-Month Change-11.38%
    5-Year Change-93.71%
    Total Return (1Y)-23.74%
    Total Return (3Y CAGR)-45.42%
    Total Return (5Y CAGR)-43.00%
    Max Drawdown (1Y)-52.52%
    Max Drawdown (3Y)-92.64%
    Sharpe Ratio (1Y)-0.47
    Correlation with SPY (1Y)0.21
    50-Day Average$1.03
    200-Day Average$0.85
    52-Week Range$0.50 to $1.50
    RSI (14 Days)39.2
    Average Volume (20 Days)140.84K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.61x current liabilities.

    Current Ratio0.61x
    Quick Ratio0.45x
    Interest Coverage-3.74x

    Returns and Efficiency

    Return on invested capital is -103.26% over the last 12 months, against a 5-year average of -52.40%.

    Return on Assets (ROA)-84.61%
    Return on Invested Capital (ROIC)-103.26%
    ROA (5Y Average)-53.94%
    ROIC (5Y Average)-52.40%
    Asset Turnover1.41x
    Inventory Turnover2.20x
    Receivables Turnover8.27x
    Cash Conversion Cycle171 days

    Scores

    TELA has an Altman Z-Score of -13.11, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-13.11
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $78.18M over the last 12 months is up 1.46% from the 12 months before.

    Revenue$78.18M
    Revenue Growth (YoY)+1.46%
    Gross Profit$52.53M
    Operating Income-$33.75M
    Pretax Income-$41.51M
    Net Income-$41.88M
    EBITDA-$31.73M
    EBIT-$32.76M
    Reported EPS (TTM)-$0.71

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$22.66M
    Total Debt$56.30M
    Net Debt$33.63M
    Net Debt Per Share$0.58
    Working Capital-$28.26M
    Shareholder Equity-$24.58M
    Tangible Book Value-$25.65M
    Total Assets$49.49M
    Total Liabilities$74.07M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $276.00K of capital spending, operating cash flow left -$34.39M of free cash flow.

    Operating Cash Flow-$34.11M
    Capital Expenditures$276.00K
    Free Cash Flow-$34.39M
    FCF Per Share-$0.76
    Depreciation and Amortization$1.02M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -43.17%, against a 5-year average of -72.16%.

    Gross Margin67.19%
    Operating Margin-43.17%
    Pretax Margin-53.10%
    Net Margin-53.57%
    EBITDA Margin-40.59%
    EBIT Margin-41.90%
    FCF Margin-43.99%
    Gross Margin (5Y Average)66.51%
    Operating Margin (5Y Average)-72.16%
    Net Margin (5Y Average)-80.54%

    Growth

    Revenue grew 24.68% a year over 3 years.

    Revenue Growth (3Y CAGR)+24.68%
    Revenue Growth (5Y CAGR)+34.54%
    Book Value Per Share Growth (2Y CAGR)-60.20%
    Tangible Book Per Share Growth (2Y CAGR)-62.58%

    Revenue and profit by year

    Dividends and Yields

    TELA does not pay a dividend. Its free cash flow yield is -78.22%.

    FCF Yield-78.22%
    Buyback Yield0.45%
    Shareholder Yield0.45%

    Peer Position

    Against 11 similar companies, TELA has the 10th highest P/S.

    P/S Ratio0.6x vs 1.3x median
    ROIC-103.26% vs -111.14% median
    Revenue Growth (Trailing 4 Quarters, YoY)+1.46% vs +9.15% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 1.84% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+1.84%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About TELA

    What is TELA's market cap?

    Tela Bio has a market cap of $34.42M. Its enterprise value, which adds debt and subtracts cash, is $68.05M.

    How many shares of TELA are outstanding?

    Tela Bio has 57.69M shares outstanding. The count is up 27.01% from a year earlier.

    Does TELA pay a dividend?

    No. Tela Bio does not pay a dividend.

    How much debt does TELA have?

    Tela Bio has $56.30M of total debt and $22.66M of cash and equivalents, a net debt position of $33.63M.